Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Monocytes infiltrate gliomas but differentiate into immunosuppressive macrophages, promoting tumor growth.
• Redirecting monocyte differentiation presents a therapeutic strategy for glioma.
• M1-polarized macrophage-derived extracellular vesicles (M1-EVs) can induce anti-tumor macrophage differentiation.

Purpose of the Study:

• To engineer M1-EVs for enhanced glioma targeting and anti-tumor efficacy.
• To overcome limitations of M1-EVs, including poor BBB penetration and CD47-mediated inhibition.
• To establish a platform technology for directing monocyte differentiation against glioma.

Main Methods:

• M1-EVs were engineered with tumor-targeting chimeric antigen receptors (CARs) and CD47-blocking SIRPα variants (M1-CS-EVs).
• Dual-targeting EVs were evaluated for blood-brain barrier (BBB) penetration and glioma accumulation.
• Therapeutic efficacy was assessed in orthotopic glioma models, measuring immune response, phagocytosis, tumor growth, and survival.

Main Results:

• Engineered M1-CS-EVs demonstrated enhanced BBB penetration and glioma accumulation.
• M1-CS-EVs effectively disrupted CD47-SIRPα interactions, promoting phagocytosis.
• Treatment with M1-CS-EVs significantly suppressed tumor growth and prolonged survival in preclinical glioma models.

Conclusions:

• Dual-targeting M1-CS-EVs represent a promising platform for glioma therapy.
• This approach redirects monocyte differentiation towards an anti-tumor phenotype.
• The engineered EVs offer a broadly applicable strategy for treating gliomas.